Novartis Cosentyx Shows Strong Remission Rates in PMR Clinical Trial

Key Facts

In a move that strengthens its inflammatory disease portfolio, Novartis announced positive clinical trial results for its drug Cosentyx. According to data published in the New England Journal of Medicine, the trial demonstrated that the drug achieved sustained remission in twice as many patients suffering from Polymyalgia Rheumatica (PMR) compared to the placebo group. The study aims to establish Cosentyx as a viable treatment option for this chronic inflammatory condition.

This development comes as major pharmaceutical firms compete to expand the indications of their blockbuster drugs, with Novartis facing competition from peers like Sanofi and Regeneron, whose drug Dupixent has recently secured approvals in related fields per market data. The success of Cosentyx in this trial is a significant addition to the company's pipeline, especially as the drug already contributes substantially to Novartis' immunology revenue.

Regarding stock performance, NVS was priced at $104.20 (at close June 2, 2026). Investors are now watching for regulatory filings based on this data, while also monitoring the U.S. Core PCE Price Index release on May 28, 2026, which could impact broader market sentiment for the healthcare sector.